Mid-term results of giant cell tumours with pathologic fractures around the knee: a multicentre retrospective study.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: The authors declare that they have no conflict of interest. 7. Acta Orthop Traumatol Turc. 2019 Sep;53(5):376-380. doi: 10.1016/j.aott.2019.05.005. Epub 2019 Jun 26. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities. Campanacci L(1), Sambri A(2), Medellin MR(3), Cimatti P(1), Errani C(1), Donati DM(1). Author information: (1)Istituto Ortopedico Rizzoli, Bologna, Italy. (2)Istituto Ortopedico Rizzoli, Bologna, Italy. Electronic address: andrea_sambri@libero.it. (3)Clinica Nueva, Bogota, Colombia. OBJECTIVES: The aim of this study was to describe the cohort of patients who have been treated with Denosumab as neoadjuvant therapy prior to surgery for aggressive giant cell tumor of bone in the extremities, to evaluate the radiological responses to Denosumab comparing Choi criteria and a newly described computerized tomography (CT) classification, and to evaluate the risk of local recurrence after intralesional curettage or radical excision. METHODS: We retrospectively evaluated 36 patients (20 females and 16 males; mean age at diagnosis 36 years (range, 18-64)) treated with neoadjuvant Denosumab therapy prior to surgery for aggressive giant cell tumor of bone in the extremities. The radiological responses to Denosumab treatment were analyzed on the preoperative images after the neoadjuvant course with the Choi criteria and with a newly proposed classification based on CT. All these images were independently reviewed by two of the researchers. Surgical intervention methods were noted and local recurrence rates were evaluated. The correlation between radiological response amount and local recurrence were analyzed for both Choi criteria and the new CT classification. RESULTS: Denosumab was administered for a mean of 21 weeks (range 7-133). Five patients also had a short postoperative course. According to Choi criteria there was a radiological response in 32 patients (89%), while the new CT classification identified responses in all the 36 patients (100%). The identification of changes after 7 weeks of treatment was higher using the CT classification compared to Choi criteria (p = 0.043 vs p = 0.462). The surgical interventions after Denosumab comprised curettage in 29 patients (74%) and resection in 7 (26%). Local recurrence was higher in patients managed with intralesional curettage than in those treated with en bloc resection (55.1% vs 0%, p